TY - JOUR
T1 - Use of olanzapine for the relief of nausea and vomiting in patients with advanced cancer
T2 - a multicenter survey in Japan
AU - Kaneishi, Keisuke
AU - Nishimura, Kazunori
AU - Sakurai, Norio
AU - Imai, Kengo
AU - Matsuo, Naoki
AU - Takahashi, Naoko
AU - Okamoto, Kenichiro
AU - Suga, Akihiko
AU - Sano, Hiromi
AU - Maeda, Isseki
AU - Nishina, Haruhiro
AU - Yamaguchi, Takuhiro
AU - Morita, Tatsuya
AU - Iwase, Satoru
PY - 2016/6/1
Y1 - 2016/6/1
N2 - Nausea and vomiting are among the most common and distressing symptoms in patients with advanced cancer. Olanzapine, an antipsychotic agent, is known to have an affinity for multiple neurotransmitter receptors. Previous studies have reported olanzapine to be efficacious in the treatment of nausea and vomiting. Although it has been administered at a number of facilities, its applicability to treat nausea and vomiting in patients with advanced cancer is poorly understood. We investigated the use of olanzapine for nausea and vomiting in patients with advanced cancer at multiple centers. This retrospective study was carried out at seven palliative care units and three facilities with palliative care teams in Japan from 2013 to 2015. The dosage of olanzapine, treatment duration, and duration from initial use until death were collected from the medical records. One hundred and eight patients met our inclusion criteria. The average dose of olanzapine was 3.6 mg (2.5 mg, n = 61; 5 mg, n = 46; 10 mg, n = 1) and average treatment duration was 18.7 days. The average duration from initial use until death was 39.0 days. There were no differences in the duration of administration until death between olanzapine doses (2.5 and 5 mg). Our results suggest that olanzapine have been used in patients with poor prognoses for nausea and vomiting in patients with advanced cancer. Conducting a prospective trial would further yield promising results.
AB - Nausea and vomiting are among the most common and distressing symptoms in patients with advanced cancer. Olanzapine, an antipsychotic agent, is known to have an affinity for multiple neurotransmitter receptors. Previous studies have reported olanzapine to be efficacious in the treatment of nausea and vomiting. Although it has been administered at a number of facilities, its applicability to treat nausea and vomiting in patients with advanced cancer is poorly understood. We investigated the use of olanzapine for nausea and vomiting in patients with advanced cancer at multiple centers. This retrospective study was carried out at seven palliative care units and three facilities with palliative care teams in Japan from 2013 to 2015. The dosage of olanzapine, treatment duration, and duration from initial use until death were collected from the medical records. One hundred and eight patients met our inclusion criteria. The average dose of olanzapine was 3.6 mg (2.5 mg, n = 61; 5 mg, n = 46; 10 mg, n = 1) and average treatment duration was 18.7 days. The average duration from initial use until death was 39.0 days. There were no differences in the duration of administration until death between olanzapine doses (2.5 and 5 mg). Our results suggest that olanzapine have been used in patients with poor prognoses for nausea and vomiting in patients with advanced cancer. Conducting a prospective trial would further yield promising results.
KW - Cancer
KW - Nausea
KW - Olanzapine
KW - Palliative care
KW - Vomiting
UR - http://www.scopus.com/inward/record.url?scp=84973890034&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84973890034&partnerID=8YFLogxK
U2 - 10.1007/s00520-016-3101-x
DO - 10.1007/s00520-016-3101-x
M3 - Article
C2 - 26838020
AN - SCOPUS:84973890034
VL - 24
SP - 2393
EP - 2395
JO - Supportive Care in Cancer
JF - Supportive Care in Cancer
SN - 0941-4355
IS - 6
ER -